Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If Ken keeps to what he has been doing for some time now, a PR would be out around 10:30. Although it is great to get them during trading hours, it would be nice to see him mix it up for a change.
Here we go!!!!!!!!!!
This will not be a Pink Sheet stock for very long. I expect uplisting to become a reality in the very near future.
Volume is looking better and things are real tight. A breakout is imminent IMO.
I am looking for a strong week here if up-listing or another major event is PR'd. Otherwise it should be more of the same floating around in the .05's.
GLTA!
More MCLN (.022) NEWS- MedClean Technologies (OTC Bulletin Board: MCLN), the leading provider of onsite technology for the treatment and disposal of medical waste and the destruction of confidential documents and related media, announced today a co-marketing agreement with Green Umbrella Solutions, a premier provider of innovative technology and services for HIPAA document destruction and recycling.
"The combination of Green Umbrella's full service HIPAA document destruction and recycling capabilities, coupled with MedClean's industry leading sterilization and waste reduction technology, further strengthens and broadens our green capabilities in the marketplace," commented Dave Laky, President and CEO of MedClean Technologies, Inc. "Working together the two companies combine to provide a unique one stop shop green solution that serves a common set of customers in the health care community who appreciate the benefits of lower costs, less risk, and higher quality when compared to traditional offsite hauling solutions. We anticipate additional access to health care opportunities through this relationship, enabling MedClean to achieve its objective for more than 100% compounded annual revenue growth over the next five years."
John Ulitsch, Green Umbrella Solutions, added, "Our customized, full-service solutions complement MedClean's onsite medical disposal technology, reducing our customers costs and enhancing their green profile through recycling. In addition, both organizations are now positioned to establish a single, full-service contract with our customers and with Group Purchasing Organizations (GPO) that will maximize costs savings while ensuring optimal operational productivity. We look forward to a long, mutually rewarding relationship that improves the quality of life for all of us."
About Green Umbrella Solutions
Green Umbrella Solutions, headquartered in Atlanta, GA is the most environmentally sound, cost effective, document shredding company in the world. As an industry leader, we offer our partners tailor-made, affordable solutions without compromising quality, the integrity of confidential information, or the environment. By strictly adhering to industry security standards, our partners are guaranteed the highest level of document protection each and every time. To learn more, visit www.greenumbrellasolutions.com.
About MedClean Technologies, Inc.
MedClean Technologies, Inc. is a provider of innovative technology and services for the onsite treatment and disposal of regulated medical waste. MedClean's flagship MedClean(R) Series systems are fully integrated, turnkey technology solutions that enable hospitals and other healthcare providers to safely, efficiently, and cost-effectively convert bio-hazardous regulated medical waste into sterile, unrecognizable material suitable for disposal as municipal solid waste. MedClean was founded in 1997 with corporate headquarters, research and development and distribution facilities located in Bethel, Connecticut. Further, information on MedClean can be found at www.medcleantechnologies.com and in filings with the Securities and Exchange Commission found at www.sec.gov.
Statements about our future expectations are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words "may," "will," "should," "anticipate," "believe," "appear," "intend," "plan," "expect," "estimate," "approximate," "potential" and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2009, filed with the SEC on March 3, 2010, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.
Very heavy buy volume coming in now. It looks like a breakout is imminent.........
I really like the volume today. I just added some and averaged down quite a bit. Looking forward to news and/or financials very soon.
NEPH NEWS- Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today reported that is has entered into a development agreement with STERIS Corporation (NYSE: STE).
Under the terms of the agreement, Nephros and STERIS will jointly develop filtration-based products for medical device applications. Nephros received an initial payment upon entering into the agreement and is eligible to receive additional payments upon successful completion of product development milestones.
"Nephros is investigating a range of commercial, industrial and retail opportunities for its DSU technology," said Ernest Elgin, President and CEO of Nephros. "We are pleased to be working with STERIS to leverage our expertise in additional applications. STERIS is a leader in the field of medical device sterilization, and we look forward to developing new products together to enhance patient safety."
In 2009, Nephros received 510(k) marketing approval from the FDA for the Dual Stage Ultrafilter (DSU) to be used to filter biological contaminants from water and bicarbonate concentrate used in hemodialysis procedures. In August 2009, Nephros reported that it was awarded a new research contract from the U.S. Office of Naval Research ("ONR") for development of a portable dual-stage purifying filter.
About STERIS
The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company has approximately 5,000 dedicated employees around the world working together to supply a broad array of solutions by offering a combination of equipment, consumables and services to healthcare, pharmaceutical, industrial and government Customers. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit www.steris.com.
About Nephros, Inc.
Nephros, Inc., headquartered in River Edge, New Jersey, is a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification. The Nephros DSU is the basis for the Nephros line of water filtration products. The patented dual stage ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses, parasites and biotoxins.
For more information about Nephros, please visit our website at http://www.nephros.com.
As soon as weather allows for it. Things are going to get very interesting around here in the near future.
Based on what? Let me guess......... absolutely nothing of substance.
Great call on SOMX Sheff! I sold for a handsome 100% profit today.
I am quite surprised at how well we held up today. Looking forward to more specific info on the Stanley contract in the coming days!
Today was the bread and water served before the drink or appetizer! :)
KATX NEWS- Kat Exploration Inc. (PINKSHEETS: KATX) www.katexploration.com
The company would like to inform its investors that it has put out a call for tenders on its upcoming drill program for its Handcamp gold property. Three bids will be submitted to the company in which the board of directors will select the appropriate choice.
The drill program will commence as soon as ground conditions are favorable and all permits are in place.
For the past several weeks the company has engaged the assistance of a contracted geologist to compile all property data in order to outline favorable drill targets and to submit all government applications for the approval of mobilizing drill rigs to the site.
As this project moves forward the company will update its shareholders when new information becomes available.
This press release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Kat Exploration Inc. to be materially different from the statements made herein.
Contact:
Ken Stead
President / CEO
Kat Exploration Inc.
Office: 709-368-9223
709-368-9224
Fax: 709-368-9213
www.katexploration.com
kstead@katexploration.com
.06 EOM
Based on the fact that I was sure we would already be in the sub-penny area by now, I think it is possible that this doesn't get there at all. It all depends on how many fluff PR's (or even ones of substance) Ray Ray can squeeze out. If I had to guess, I would say this might bottom out in the .01 to .02 range. I still have a bit of a score to settle here, but I am not going to jump the gun getting back in. Patience almost always pays off.
MUST READ:
Although this is in the I-Box, many people may overlook this interesting comparison put together by Sterling (stervc). Keep in mind that this does not take into account today's development and was written 9/2/09. BTW L-1 Identity Solutions Inc. closed today at $9.25 a share.
EVRM vs ID:NYSE**Compare & Contrast…
(Revision #2)
I think in order for people to understand how undervalued EVRM still is at these price levels in my opinion, I think one should compare and contrast EVRM to L-1 Identity Solutions Inc. which trades on the NYSE under the ticker of ID which last closed at $6.90 per share with their very inferior Iridian technology as compared to EVRM’s far superior biometrics patented technology. Below is much that we all should consider to compare and contrast in detail to fully understand the maturity that I think EVRM is finally about to experience.
Market Consideration to Compare & Contrast
L-1 Identity Solutions Inc. trades on the NYSE under the ticker of ID:
http://finance.yahoo.com/q?s=id
Evermedia Group, Inc. trades on the pink sheets under the ticker of EVRM:
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=evrm
Market Cap Consideration to Compare & Contrast
According to ID’s last quarterly report, their Outstanding Shares (OS) was in the amount of 90,526,215 shares. Currently, ID:NYSE trades at $6.90 per share. That’s a Market Cap of below:
http://ir.l1id.com/financials-keyratios.cfm
http://ir.l1id.com/results.cfm
90,526,215 shares (OS) x $6.90 = ID Market Cap
$624,630,884 = ID Market Cap
EVRM Outstanding Shares (OS) is in the amount of 657,942,839 shares. As of right now, EVRM is at .031 per share. That’s a Market Cap of below:
657,942,839 shares (OS) x .031 = EVRM Market Cap
$19,363,557 = EVRM Market Cap
So…
ID Market Cap = $624,630,884
EVRM Market Cap = $19,363,557
So… to mathematically Compare & Contrast…
ID Market Cap of $624,630,884 = EVRM Market Cap of $19,363,557
$624,630,884 ÷ $19,363,557 = EVRM Undervaluation Consideration to ID:NYSE
32.26 = EVRM Undervaluation to ID by Market Cap Comparison
The above means that EVRM is ”potentially” 32.26 times undervalued in price in comparison to the $6.90 share price where ID:NYSE is trading at right now. Is this saying that EVRM should be trading at $6.90 per share? No it’s not!!! However, it is saying to me that EVRM should at the very least be somewhere much higher for starters and not here at .031 per share especially since they have a far superior patented technology. Now let’s compare and contrast EVRM’s technology against ID’s. This information below is also in the EVRM IBox about their eye scanner:
Mathematical Transforms used in Iris Extraction to Compare & Contrast
** ID:NYSE uses the Gabor Transform which is a very antiquated and less accurate version which requires more data storage per dimensions and characteristics.
** EVRM uses the Daubechies Wavelet Transform. This technology is the most accurate process for extracting fine iris characteristics because of using less data storage.
Quantization Methods to Compare & Contrast
** ID:NYSE under their Iridian biometrics technology uses 2-level quantization.
** EVRM under their patented biometrics technology uses N-level quantization.
Live Person Validation to Compare & Contrast
** ID:NYSE under their Iridian technology does not do “Live Person” Validation.
** EVRM under their patented biometrics technology actually does “Live Person” validation by analyzing pupil contraction and dilation to ensure that the scan is of a live iris.
Encoded Iris Data Storage Size to Compare & Contrast
** ID:NYSE under their Iridian technology has a storage size of 256 Bytes.
** EVRM under their patented biometrics technology has a storage size of 81 Bytes.
Validation of Scanned Iris Against Database to Compare & Contrast
** ID:NYSE under their Iridian technology uses a Hamming distance based on algorithm to compare a scanned iris against its iris database.
** EVRM under their patented biometrics technology performs the Daubechies Wavelet Transform of the iris image to extract the iris features and compares the results against the stored iris data.
In Summary
ID:NYSE is at $6.90 per share and EVRM is at .031 per share. I think I need to reiterate that the Market Cap for ID:NYSE is $624,630,884 as compared to an EVRM Market Cap of $19,363,557. This is a Market Cap that is 32.26 times lower than ID’s Market Cap with EVRM having a much more up to date and far superior patented technology. This is also why I think EDS/HP, CACI, Honeywell, US Navy, Stanley, PKI Institute, and many others have made the decision to partner with EVRM versus ID:NYSE. This could mean that EVRM could justify trading in the area of…
32.26 x .031 per share = $1.00006 per share
I am guessing that as details are announced about their contracts, $1.00006 per share might not be high enough as from researching the history of EDS/HP, CACI, Honeywell, US Navy, Stanley, PKI Institute, and many others they have partnered with. They are in bed with quite a few multi-billion dollar companies and organizations.
I am guessing that eventually now that EVRM is riding the coat tails of their partners, other multi-billion dollar companies will follow suit by researching EVRM’s patented technology to offer EVRM more contracts too. I think it’s just a matter of time before they are discovered by many more companies and investors.
From my understanding, their partnership with EDS has opened the doors for them to partner with the remaining companies approved to service the US Army’s Biometrics Operations and Support Services Unrestricted (BOSS-U) for multiple contract awards to fill specific Tasking Orders such as Lockheed Martin, Northrop Grumman, Raytheon Company, Computer Sciences Corporation (CSC), American Systems Corporation, Booz Allen Hamilton, CACI, Cogent, Ideal Innovations, SAIC, and Telos Corporation. I think it would be wise to be on the lookout for future unions confirmed to have been made between EVRM and these multi-billion dollar companies.
Again, with the compare & contrast thoughts posted above between EVRM and ID:NYSE, I was not trying to say that since ID trades on the NYSE at $6.90 per share that EVRM should trade at such prices too since they have a far superior technology. However, I am saying that EVRM maybe should be trading somewhere commensurate to its potential at much higher prices and not here at .031 per share. I think once EVRM announces just a little more confirmed substance, then this value would be captured.
v/r
Sterling
WOW! And to think I almost sold for a loss a few days ago after months of frustration. Patience does pay off at times.
I will be holding this for a while as this news has not even been PR'd by EVRM yet, and it's particulars not even revealed. Things could get VERY interesting here in the coming days/weeks. This stock just got a ton of recognition!
YES, and this should be no surprise to anyone here.
Still waiting for a re-entry point.............
Haha, good to see you back.
We need some KABOOOOOOOOOM's here!
Nope, there are two of us morons here. :)
I really like the CSLI technology and that is why I will continue to hold for the time being.
VOL OVER 8 MIL IN FIRST 15 MIN!!
Eyes are back on this stock and we could see a big multi-day (or week) run.
MCLN- +28% ON HUGE VOLUME
.0248 X .0268 eom
MCLN- Agreed, but I like this even more:
"We have also activated our new product development program, which will deliver a solution appropriate for some 200,000 targets in the underserved market segment of healthcare institutions and providers generating less than 100,000 pounds of medical waste annually"
To me this means that they are developing a system of medical waste management for smaller health care operations like large doctor offices and health clinics. IMO THIS COULD BE REALLY BIG! Just think about the potential!
"We have also activated our new product development program, which will deliver a solution appropriate for some 200,000 targets in the underserved market segment of healthcare institutions and providers generating less than 100,000 pounds of medical waste annually"
To me this means that they are developing a system of medical waste management for smaller health care operations like large doctor offices and health clinics. IMO THIS COULD BE REALLY BIG! Just think about the potential!
MedClean Technologies Announces Record 2009 Financial Results
Revenue Increases 21.4%, Gross Margin Improves 170% Driving Improved Operating Results
By: PR Newswire
Mar. 4, 2010 08:01 AM
BETHEL, Conn., March 4 /PRNewswire-FirstCall/ -- MedClean Technologies, Inc. (OTC Bulletin Board: MCLN) today announced financial results for the Company's year ended December 31, 2009.
Financial Highlights:
Full-year revenue increased 21.4% to $2.5 million from $2.1 million last year
Gross margin increased to 50.3% from 18.6% for FY 2008
Net loss for the year was $(5.4) million, or $(0.01) per share vs. a loss of $(7.8) million, or $(0.03) per share last year.
Full Year Financial Results
The Company reported revenue of $2.5 million, an increase of 21.4% compared to $2.1 million for the year ended December 31, 2008. Gross profit for 2009 was $1.3 million, or 50.3% profit margin, compared to gross profit of $390,000, or 18.6% profit margin, in the prior-year period. The increase in gross margin represents a 170%, or 3,170 basis point improvement. Net loss for the full-year was $(5.4) million, or $(0.01) per share, compared to a net loss of $(7.8) million, or $(0.03) per share for the same period in 2008.
In addition, operations for the second half of 2009, July 1, 2009 through December 31, 2009, net of one-time severance fees $(200,000), one-time stock based finance fees related to the Socius financing transaction $(619,389) and legal/professional fees not related to operations $(33,000) resulted in earnings, excluding these non-recurring costs of $36,149. Cash used in operations averaged $288,000 per month for the first six months of 2009, while cash used in operations was reduced to an average of $30,000 per month for the second six months of 2009. The reduction in cash usage was a result of cash received from increased sales and improved margins coupled with strong expense management.
"During 2009, the company took measures to reduce non-essential operating expenses through staff reduction and the outsourcing of certain business functions," said David Laky, MedClean's President and Chief Executive Officer. "The net effect of the expense reduction programs and business restructuring began to take effect in the second half of 2009 as evidenced by our results. We have positioned MedClean to capitalize on the many opportunities available for growth in the more than $4 billion annual U.S. market for medical waste disposal and confidential document destruction. Our strategy resulted in revenue growth, higher gross margins, and improved operating results driven by effective operational management."
"We believe that as healthcare institutions increasingly look for ways to reduce costs and address environmental issues, MedClean will deliver solutions that meet these objectives," added Mr. Laky. "To enhance our ability to do so, the Company secured a $7.5 million capital commitment, which will allow us to accelerate our growth through direct sales and a focused distribution network of partners. We expect to become the leader in the onsite treatment and disposal of regulated medical waste and HIPAA document destruction. We believe that today we have a differentiated business model, experienced management team, ground breaking technology, balanced distribution channels and access to capital to achieve our objective of more than 100% compounded annual growth over the next five years while achieving 40% to 50% EBITDA. MedClean's differentiated business model, featuring capital purchase, lease, and rental solutions, is generating significant interest from both end-users and distribution partners, which has translated into significant potential sales activity and a pipeline with a strong recurring revenue component. We have also activated our new product development program, which will deliver a solution appropriate for some 200,000 targets in the underserved market segment of healthcare institutions and providers generating less than 100,000 pounds of medical waste annually. We are excited about the opportunities in 2010 and beyond as we believe that the Company has the right products, marketing strategy and management team to become a leader in the industry."
Fourth Quarter Financial Results:
The Company reported revenue of $219,000 for the fourth quarter of fiscal 2009, an increase of 53% compared to $143,000 for the fourth quarter last year. Gross profit for the fourth quarter of 2009 was $111,000, or 50.9% profit margin, compared to gross profit of $(259,000), or (181%) profit margin, in the prior-year period. Net loss for the fourth quarter was $(1,138,696), or $(0.00) per share, compared to a net loss of $(3.5) million, or $(0.01) per share for the same period in 2008.
"We are pleased with our accomplishments in 2009, a year of transformation that created the foundation for the company to leverage new capital to accelerate growth and exceed our objectives over the next five years," commented Mr. Laky.
2009 Accomplishments:
Strengthened Business Model
Through expense reduction and restructuring the management team, the Company lowered break-even levels, setting the stage for investing capital into revenue-generating activities and for the continued development of new, exciting solutions that expand its market opportunity.
MedClean introduced new equipment acquisition options. Customers can now acquire MedClean products without capital outlay. The Company's new rental and usage programs eliminate lengthy procurement processes and provide the Company with the basis for a strong recurring, predictable, revenue model year over year.
MedClean strengthened the balance sheet through securing a $7.5 million commitment from Socius Life Sciences Capital Partners. Under this agreement, the Company may sell Series C Preferred Stock over a two-year period. The proceeds are expected to be used for revenue generating activities and support the Company's entry and growth into new emerging markets.
The Company took the steps required to protect its unique product distinctions. MedClean is in the patent process for the protection of product distinctions unique to the containerized process for the sterilization and destruction of regulated medical waste, including sharps and confidential documentation. The Company is engaged in the same patent process to protect the efficacy protocol which governs the treatment cycle during the sterilization process in a very efficient manner and timeframe.
Expansion into target markets
MedClean was approved to proceed with sales and installation efforts in New Jersey following a joint authorization issued by the state Department of Environmental Protection and Department of Health and Senior Services. This approval now positions MedClean with the ability to offer their new guaranteed savings program to facilities in every state in the U.S.
The Company completed the sale and installation of a service bureau configuration on the island of Puerto Rico. The service bureau configuration demonstrates the scalability of the MedClean solution and positions the company as a provider for similar configurations domestically and in the target rich international market.
The Company continued to develop its Group Purchasing Organization (GPO) network to ensure rapid acceptance of the company's ground-breaking technology. As an example, MedClean is the only onsite medical waste disposal solution certified by MedAssets, a GPO that provides services to improve operating margins and to decrease supply expenses for over 1,500 healthcare provider organizations nationwide.
The Company has filed its Form 10-K for the period ended December 31, 2009 with the Securities and Exchange Commission, and investors are encouraged to visit www.sec.gov to review this document, which includes financial tables and additional detail for the year ended December 31, 2009.
About MedClean Technologies, Inc.
MedClean Technologies, Inc. is a provider of innovative technology and services for the onsite treatment and disposal of regulated medical waste and HIPAA document destruction. MedClean's flagship MedClean® Series systems are fully integrated, turnkey technology solutions that enable hospitals and other healthcare providers to safely, efficiently and cost-effectively convert bio-hazardous regulated medical waste into sterile, unrecognizable material suitable for disposal as municipal solid waste. MedClean was founded in 1997 with corporate headquarters, research and development and distribution facilities located in Bethel, Connecticut. Further information on MedClean can be found at http://www.medcleantechnologies.com and in filings with the Securities and Exchange Commission found at http://www.sec.gov.
Statements about our future expectations are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words "may," "will," "should," "anticipate," "believe," "appear," "intend," "plan," "expect," "estimate," "approximate," "potential" and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2009, filed with the SEC on March 3, 2010, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.
Contact:
Cameron Donahue
Hayden IR
(651) 653-1854
SOURCE MedClean Technologies, Inc.
What is really frustrating me with MCLN is the lack of communication from the company. Earnings are due out within the next four weeks, and we as shareholders really have very little to go on in determining how well this company has performed. It my view, these earnings are pretty much a crap shoot. I am holding a large "free" position here so I will hold through the earnings, but I feel like it is really like rolling the dice. If it weren't for the outstanding track record of this management team I would have taken all my profits here and run for the hills a while ago.
GLTA
I think we have had plenty of "solid ground" in the .05's and .06's. And this "solid ground" is what has made this penny act like a "real stock" as you describe. IMO the expectations here are HUGE, thus creating a very demanding audience that is looking for the blockbuster news of a JV or partnership. However, that does not mean we can't have a nice move any day to .10 and beyond, but to get to .20+++ we will need the real big PR to hit the news wires.
.064 X .065 EOM
I am no mining expert, but after comparing these results to some others I have found online, Handcamp looks very very impressive in comparison.
This week should be quite interesting indeed.
I am still in EVRM, but it has not been an easy decision. I have added a few times on the way down to lower my cost basis, and I am considering adding more tomorrow. I know things don't appear to be going anywhere fast with this company, but I believe there is too much potential here to just walk away with a loss. I also like the fact that they have not dumped shares recently.
Time will tell............
I am not trying to "mislead" anyone Joe, don't be so quick to accuse somebody who made a honest mistake. I saw the list on another board and noticed VKNG on it so I shared it with this board.
Mods please delete my previous post.
VKNG #8 on Naked Short List
http://www.buyins.net/tools/short_list.php?ssd=20091202
That was done a while ago. But I agree, it is very interesting indeed.
Does anyone know the updated share structure? Hopefully it has remained the same.
Don't worry, your not alone. I am in love with the potential here because it is truly amazing when you look at the entire picture.
Agreed, excellent post Er0ck!
AMAZING NEWS! .10++ TODAY eom